Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China.
Int J Mol Med. 2023 Sep;52(3). doi: 10.3892/ijmm.2023.5289. Epub 2023 Aug 4.
N6‑methyladenosine (m6A) RNA methylation is one of the most common post‑transcriptional modification mechanism in eukaryotes. m6A is involved in almost all stages of the mRNA life cycle, specifically regulating its stability, splicing, export and translation. Methyltransferase‑like 14 (METTL14) is a particularly important m6A methylation 'writer' that can recognize RNA substrates. METTL14 has been documented to improve the activity and catalytic efficiency of METTL3. However, as individual proteins they can also regulate different biological processes. Malignancies in the digestive system are some of the most common malignancies found in humans, which are typically associated with poor prognoses with limited clinical solutions. METTL14‑mediated methylation has been implicated in both the potentiation and inhibition of digestive system tumor growth, cell invasion and metastasis, in addition to drug resistance. In the present review, the research progress and regulatory mechanisms of METTL14‑mediated methylation in digestive system malignancies were summarized. In addition, future research directions and the potential for its clinical application were examined.
N6-甲基腺苷(m6A) RNA 甲基化是真核生物中最常见的转录后修饰机制之一。m6A 参与 mRNA 生命周期的几乎所有阶段，特异性调节其稳定性、剪接、输出和翻译。甲基转移酶样蛋白 14(METTL14)是一种特别重要的 m6A 甲基化“书写器”，可识别 RNA 底物。已有文献记载，METTL14 可提高 METTL3 的活性和催化效率。然而，作为单个蛋白，它们也可以调节不同的生物学过程。消化系统恶性肿瘤是人类最常见的恶性肿瘤之一，通常预后不良，临床解决方案有限。METTL14 介导的甲基化在促进和抑制消化系统肿瘤生长、细胞侵袭和转移以及耐药性方面都有涉及。本综述总结了 METTL14 介导的甲基化在消化系统恶性肿瘤中的研究进展和调控机制。此外，还探讨了其未来的研究方向及其在临床应用中的潜力。
